Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy. by Fraaij, P.L. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/48438
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
604 • CID 2005:40 (15 February) • HIV/AIDS
H I V / A I D S B R I E F R E P O R T
Sustained Viral Suppression and
Immune Recovery in HIV Type 1–
Infected Children after 4 Years of
Highly Active Antiretroviral Therapy
Pieter L. A. Fraaij,1 Gwenda Verweel,1 Annemarie M. C. van Rossum,1
Ellen G. van Lochem,2 Martin Schutten,3 Corry M. R. Weemaes,4
Nico G. Hartwig,1 David M. Burger,5 and Ronald de Groot1
1Department of Pediatrics, Erasmus Medical Center–Sophia Children’s Hospital,
Departments of 2Immunology and 3Virology, Erasmus MC, Rotterdam, and
Departments of 4Pediatrics and 5Clinical Pharmacy, Nijmegen University Center
for Infectious Diseases, University Medical Center, Nijmegen, The Netherlands
We report the data from a long-term study of 31 human
immunodeficiency virus type 1 (HIV-1)–infected children
who were treated with highly active antiretroviral therapy.
A high proportion of the children had undetectable HIV-1
RNA levels. CD4+ T cell counts recovered and remained
stable. Adverse events were observed frequently but were
mostly mild.
Prospective studies on the use of HAART in HIV-1–infected
children show viral suppression and recovery of the immune
system. However, the response rates in children are highly var-
iable and are frequently inferior to those observed in adults
[1]. Most studies of HIV-1–infected children do not have an
observation period that exceeds 48 weeks. Therefore, little is
known about the durability of the viral suppression and the
reconstitution of the immune system [1]. Here, we report the
results at week 192 week (year 4) of a prospective, open-label
cohort study on the clinical, immunological, and virological
response to HAART in 31 HIV-1–infected children.
Methods. Protease inhibitor (PI)–naive HIV-1–infected chil-
dren with a viral load 15000 copies/mL (measured on 2 con-
secutive occasions) and/or a CD4+ cell count that was lower than
their age-specific reference value were treated with indinavir or
nelfinavir and 2 nucleoside reverse-transcriptase inhibitors. In all
patients, steady-state intensive plasma pharmacokinetic sampling
for the specific PI was performed. Pharmacokinetic sampling was
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repeated until the area under the plasma concentration-time
curve reached target values [2]. Selected clinical data and labo-
ratory values were obtained during regular visits to the outpatient
department. Adherence to the treatment regimen was assessed
by interviews with parents and patients, with medication diaries,
and by measurements of plasma drug levels. All patients who
started treatment before 1 January 2000 were included in the
present study. The study protocol was approved by the medical
ethics committee of the Erasmus Medical Center (Rotterdam,
The Netherlands). Written, informed consent was obtained from
patients and their parents.
At each time point, the percentage of patients with HIV-1
RNA levels that were less than the detection limit was calcu-
lated. For missing data, the response value was considered to
be greater than the detection limit. Because absolute CD4+ T
cell and CD8+ T cell counts are age related, CD4+ and CD8+
T cells counts as percentages of age-specific reference values
were calculated. The patient’s individual values at the different
time points were divided by the median of the age-specific
reference values for T cell subpopulations at that time point
[3–5]. To evaluate growth, standard deviation scores (SDS) were
obtained from the Dutch reference curves.
Differences between paired variables were analyzed with the
Wilcoxon signed rank test and between groups with the Mann-
Whitney U test. The relationship between response to therapy
and baseline HIV-1 RNA level and age was evaluated using
exact binary logistic regression analysis. For statistical analysis,
SPSS, version 10 (SPSS); LogXact, version 4.1 (Cytel Software);
Excel 97 (Microsoft); and Growth analyzer software were used.
Results. During the period of January 1997 through Jan-
uary 2004, a total of 31 HIV-1–infected children started HAART
in our cohort. Their baseline characteristics are summarized in
table 1. None of the children had received prior treatment with
PIs or nonnucleoside reverse-transcriptase inhibitors.
At baseline, 28 children started HAART that included in-
dinavir, and 3 children started HAART that included nelfinavir.
Therapy was changed a total of 38 times for 28 children. Rea-
sons for changing therapy included treatment failure ( ),np 20
drug toxicity ( ), simplification of the regimen ( ),np 7 np 7
refusal and/or intolerance of the medication regimen ( ),np 3
and failure to achieve appropriate pharmacokinetic values
( ). During follow-up, patients used a median of 2 dif-np 1
ferent HAART regimens (range, 1–5 regimens). In 13 children
(41% of all patients), HAART was changed at least once be-
cause of viral failure. Six patients were lost to follow-up. Rea-
sons for study termination included death ( ), emigrationnp 1
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Table 1. Baseline characteristics of the 31 HIV-1–infected
children in a study of sustained viral suppression and immune
recovery after 4 years of HAART.
Characteristic Value
No. of subjects, male/female 16/15
Race
White 4
Nonwhite 27
Age, median years (range) 5.1 (0.2–16.4)
Route of HIV transmission
Vertical 22
Blood products 4
Unknown 5
CDC HIV disease classificationa
N1 2
N2 3
N3 1
A1 3
A2 5
A3 1
B1 2
B2 5
B3 1
C1 0
C2 2
C3 6
Prior NRTI treatment
None 15
Any 16
AZT 11
AZT and zalcitabine 2
AZT and 3TC 1
AZT and ddI 1
AZT, ddI, and 3TC 1
Initial HAART regimen
Idv, AZT, and 3TC 27
Idv, 3TC, and ddI 1
Nfv, AZT, and 3TC 1
Nfv, d4T, and ddI 2
Plasma HIV-1 RNA level,
median copies/mL (range) 87,350 (725–2,195,000)
CD4+ T cell value, median (range)
Absolute cell count, 106 cells/mL 480 (0–3580)
Percentage of normal 47 (0–143)
CD8+ T cell value, median (range)
Absolute cell count, 106 cells/mL 1240 (180–5436)
Percentage of normal 155 (27.5–745)
NOTE. Data are no. of patients, unless otherwise indicated. AZT, zido-
vudine; CDC, Centers for Disease Control and Prevention; ddI, didanosine;
d4T, stavudine; Idv, indinavir; Nfv, nelfinavir; 3TC, lamivudine.
a Clinical and immunological categories, as defined by the CDC.
Figure 1. The proportion of children whose HIV-1 RNA levels de-
creased to !500 copies/mL and !50 copies/mL in as-treated (AT) and an
intention-to-treat (ITT; missing-equals-failure) analyses.
( ), failure to come to the appointments ( ), and agenp 2 np 2
of 118 years ( ).np 1
One child died of serious invasive opportunistic infections
1 year after start of therapy. Three children had cases that
showed progression in the Centers for Disease Control and
Prevention (CDC) classification stage; none of these children
had a serious pathology. The other children in the cohort were
in good health, and a significant increase in growth was ob-
served after the start of HAART (median body mass index
DSDS, 0.44 [ ]; median height DSDS, 0.32 [ ]).Pp .019 Pp .05
Figure 1 shows the proportion of patients with HIV-1 RNA
levels that were less than the detection limits over time, assessed
using as-treated and intention-to-treat (missing-equals-failure)
analyses. After 4 years, 80% and 76% of the children had HIV-
1 levels of !500 and !50 copies/mL, respectively, in the as-
treated analysis, and 65% and 61% of the children, respectively,
had such levels in the intention-to-treat analysis. Of the 25
children who were receiving treatment after 4 years, 7 (28%)
had HIV-1 RNA levels that reached !500 copies/mL at week
12 and maintained HIV-1 RNA levels of !500 copies/mL during
the entire follow-up period. These 7 patients were all considered
to have been adherent to the treatment regimen, whereas 11
of the 18 patients who did not have complete viral suppression
were considered to have been nonadherent to therapy at least
once.
Binary logistic regression of the parameters of age, baseline
HIV-1 RNA level, and viral response revealed no relation
between the baseline HIV RNA level and therapy response
( ; ), but there was a significant negativePp .222 bp.58
relation between age and viral response rate ( ;Pp .04 bp
)..62
In figure 2A and 2C, the median CD4+ T cell count relative
to the normal value and the absolute CD4+ T cells counts (with
interquartile ranges [IQRs]) are depicted over time. Both the
median value relative to the normal value and the absolute T
cell count were significantly higher at week 192 than at baseline
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Figure 2. Median relative (i.e., percentage of normal) CD4+ (A) and CD8+ (B) T cell counts and median absolute CD4+ (C) and CD8+ (D) T cell counts
for all patients.
( for the relative CD4+ T cell count and forPp .01 Pp .025
the absolute CD4+ T cell count).
In figure 2B and 2D, the median CD8+ T cell count relative
to the normal value and the absolute CD8+ T cell count (with
IQR) are depicted. Both remained high throughout the follow-
up period and did not change significantly between baseline
and week 192 ( and respectively).Pp .96 Pp .216
T cell function was analyzed by means of proliferative re-
sponse to CD3 monoclonal antibody plus CD28 monoclonal
antibody in whole-blood lymphocyte culture [3, 6]. The level
of 3H-thymidine incorporation increased after stimulation,
from of a median of 345 counts/min/103 T cells (IQR, 134–
865 counts/min/103 T cells) at baseline to 1186 counts/min/103
T cells (IQR, 640–1528 counts/min/103 T cells) at week 192
( ). When expressed as percentages of the median, ofPp .07
3450 adult healthy donors, the T cell response increased from
a median of 17% (IQR, 7%–43%) at baseline to 59% (IQR,
32%–76%) at week 192 ( ).Pp .07
Reconstitution of CD4+ T cells (absolute CD4+ T cell count
and CD4+ T cell count as percentage of normal) was not sig-
nificantly different for virological responders and virological
nonresponders. Likewise, the absolute CD8+ T cell count did
not significantly differ between responders and nonresponders.
However, when normalized for age, starting at week 96, the
median relative CD8+ T cell count was lower in virological
responders than in virological nonresponders (figure 3). The
median CD8+ T cell percentage at week 192 was 107% (IQR,
65%–126%) in responders and 205% (IQR, 161%–255%) in
nonresponders ( ).Pp .017
During follow-up, 24 patients (77%) reported having clinical
adverse events. These were mostly mild and of gastrointestinal
origin. In 7 children, the medication regimen was changed
because of toxicity. In all cases, toxicity was associated with use
of indinavir. For 1 patient, medication was changed because of
skin rash; for all other patients, it was changed because of
nephrotoxicity, including hematuria and flank pain ( )np 4
and silent nephrolithiasis found on ultrasound examination
( ) [7]. Grade 3 or 4 laboratory adverse events were ob-np 2
served and included thrombocytopenia ( ), increased am-np 3
ylase levels ( ), and increased gamma-glutamyl transpep-np 2
tidase levels ( ). None of these resulted in a change ofnp 1
therapy.
In 2 patients, lipoatrophy was suspected on the basis of an-
thropometric measurements. Both of the children in these cases
used stavudine but different PIs (nelfinavir or indinavir). At
the 4-year time point, fasting triglyceride and cholesterol levels
could be obtained for 17 of the 25 children who were still
receiving treatment. Both levels were not markedly increased,
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Figure 3. Change from baseline CD8+ T cell count as percentage of normal in virological responders and nonresponders
with only 1 and 4 patients having cholesterol or triglyceride
levels that were greater than the upper limit of normal,
respectively.
Discussion. In the present study, a high proportion of
children had a suppressed viral load after 4 years of treatment.
Despite these good results, viral failure occurred often and
frequently required changes in therapy. Strikingly, the pro-
portion of children with a suppressed viral load increased
during follow-up. We feel that this may be because of therapy
changes and more-intensive intervention when nonadherence
was suspected.
In contrast to other studies of children with an age at baseline
similar to that of our cohort, a negative relation between age
and viral response was found [8, 9]. We speculate that puberty-
related problems that interfere with the adherence to HAART
were more likely to occur because of the longer follow-up pe-
riod in the present study.
After an initial increase, the CD4+ T cell counts remained
stable throughout the follow-up period. This indicated a du-
rable effect of HAART use on the CD4+ T cell population. The
median CD8+ T cell count and relative age-specific reference
count remained high throughout the entire follow-up period,
which indicated ongoing immune stimulation. This is different
from data obtained in studies of adults in which CD8+ T cell
counts returned to baseline levels or even decreased to less than
baseline levels after the initiation of HAART [10, 11]. Inter-
estingly, a difference in CD8+ T cell numbers as percentages of
age-related reference values was observed for patients who had
viral suppression throughout the study period and those who
had not. This difference may be the result of decreased antigenic
stimulation. However, the exact reason remains unclear and
should be subject to further study.
In conclusion, an excellent response to HAART was ob-
served. A high proportion of the children had undetectable
HIV-1 RNA levels. CD4+ T cell counts and T cell function
recovered and remained stable throughout the follow-up pe-
riod. Adverse events occurred frequently but were mostly mild.
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